Welcome to our dedicated page for Aptose Biosciences news (Ticker: APTO), a resource for investors and traders seeking the latest updates and insights on Aptose Biosciences stock.
Aptose Biosciences, Inc. (NASDAQ: APTO, TSX: APS) is a clinical-stage biotechnology company dedicated to developing precision medicines for the treatment of life-threatening cancers. This science-driven organization is focused on advancing first-in-class agents targeting acute myeloid leukemia (AML), high-risk myelodysplastic syndromes (MDS), and other hematologic malignancies. Based on a deep understanding of the genetic and epigenetic profiles of specific cancers and patient demographics, Aptose is building a robust pipeline of novel oncology therapies aimed at dysregulated processes and signaling pathways.
One of Aptose's pioneering agents, tuspetinib (TUS), is a highly potent, first-in-class pan-FLT3/BTK inhibitor. Developed as a small molecule therapeutic, tuspetinib targets various key kinases such as SYK, FLT3, JAK1/2, and mutant forms of KIT, RSK2, and TAK1-TAB1. This mechanism of action not only combats the proliferation of AML cells but also minimizes the typical cytotoxic side effects associated with conventional cancer treatments, thus enhancing the quality of life for patients.
Tuspetinib has shown significant promise in ongoing clinical trials. In the APTIVATE Phase 1/2 study, tuspetinib, both as a monotherapy and in combination with venetoclax (VEN), has demonstrated favorable safety profiles and robust efficacy in relapsed/refractory AML patients. This includes patients with various genetic mutations and those who have failed prior therapies. Notably, tuspetinib has demonstrated a 48% overall response rate when used in combination with venetoclax, making it a potential candidate for accelerated approval in difficult-to-treat VEN-resistant AML cases.
Aptose is also developing luxeptinib (CG-806), an oral, dual lymphoid and myeloid kinase inhibitor currently in Phase 1 a/b development. Luxeptinib targets relapsed or refractory hematologic malignancies and is being positioned for future clinical trials using its new generation 3 (G3) formulation, which has shown improved pharmacokinetics and tolerability.
Recently, Aptose has entered strategic financial transactions, including a public offering and private placement, to support the further development of tuspetinib and general corporate activities. With strong clinical data and robust financial backing, Aptose continues to make strides in the oncology field, aiming to bring life-saving treatments to patients in need.
Aptose Biosciences Inc. (Nasdaq: APTO) will report its financial results for the quarter ended September 30, 2021, and provide a corporate update on November 11, 2021. The company is focused on developing personalized cancer therapies, particularly in hematology. Key investigational products include luxeptinib, a first-in-class kinase inhibitor for B cell malignancies and acute myeloid leukemia, and APTO-253, which targets the MYC oncogene. The conference call will occur at 5:00 PM ET, accessible via a toll-free number or online webcast.
Aptose Biosciences has appointed Janet Clennett as Vice President of Finance and Roger Davies as Vice President of Operations. Clennett, a CPA with over 15 years of experience in finance at biotech firms, has been with Aptose since 2017. Davies brings 25 years of senior project management experience, particularly in oncology. These additions aim to strengthen Aptose's financial and operational capabilities as the company pursues growth and clinical expansion in its oncology pipeline, which includes investigational products for hematologic malignancies.
Aptose Biosciences, a clinical-stage biotech firm (Nasdaq: APTO), is set to present at two upcoming virtual conferences in September 2021. The first, the H.C. Wainwright 23rd Annual Global Investment Conference, will take place on September 13 starting at 7:00 AM EDT, with a dedicated webcast. The second, the Cantor Global Healthcare Conference, is on September 28 at 11:20 AM EDT, also featuring a webcast. These events showcase Aptose's commitment to developing cancer therapies.
Aptose Biosciences reported a net loss of $13.5 million for Q2 2021, down from $15.8 million in Q2 2020. For the six-month period, the net loss rose to $29.7 million compared to $27.3 million in 2020. Total cash and equivalents stood at $103.3 million, sufficient to fund operations into H1 2023. Key highlights include full enrollment in the Luxeptinib Phase 1a/b studies for AML and B-cell malignancies, and continued dose escalation for APTO-253 in AML/MDS. The announcement was made on August 3, 2021, ahead of a conference call scheduled for the same day.
Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS) will release its financial results for Q2 2021 on August 3, 2021, after market close. The company is focused on developing innovative cancer therapies, with two clinical-stage products targeting hematologic malignancies: luxeptinib and APTO-253. A conference call to discuss the results will be held on the same day at 5:00 PM ET, accessible via phone or webcast. Financial statements will be available on SEDAR and EDGAR.
Aptose Biosciences presented an update on its oncology pipeline on June 11, 2021, during the EHA2021 Virtual Congress. The focus was on luxeptinib, an oral FLT3 and BTK inhibitor undergoing Phase 1a/b trials for relapsed acute myeloid leukemia (AML) and B-cell malignancies. Positive results include durable MRD-negative complete response in AML and anti-tumor activity in B-cell malignancies. The company is also developing APTO-253, a MYC inhibitor, which is in Phase 1a/b trials for AML and high-risk myelodysplastic syndrome (MDS). Future updates are expected as trials progress.
Aptose Biosciences announced the results of its annual meeting held on June 1, 2021, where 72.83% of shareholders participated. All board nominees were elected, with Carol G. Ashe receiving 99.25% of votes for her position. Key resolutions passed included the reappointment of KPMG LLP as auditors, approval of the 2021 Stock Incentive Plan, and the 2021 Employee Stock Purchase Plan. Additionally, shareholders supported a non-binding resolution for executive compensation. Details on these results are available on SEDAR and EDGAR.
Aptose Biosciences (NASDAQ: APTO) announced a corporate update scheduled for June 11, 2021, at 8:00 AM ET during the EHA2021 Virtual Congress. The update will highlight clinical data for two investigational products: luxeptinib (CG-806), a FLT3 and BTK kinase inhibitor in trials for relapsed or refractory acute myeloid leukemia (AML) and B-cell malignancies, and APTO-253, a MYC repressor for patients with relapsed AML or high-risk myelodysplastic syndromes (MDS). Early clinical data will also be presented in posters on June 11, 2021.
Aptose Biosciences, a clinical-stage biotechnology firm, announced its participation in two upcoming investor conferences. The RBC Capital Markets Global Healthcare Virtual Conference is set for May 19, 2021, from 11:30 AM to 11:55 AM EDT, featuring a fireside chat with Gregory J. Renza, M.D. The Jefferies Virtual Healthcare Conference follows on June 2, 2021, at 2:00 PM EDT, where Aptose will present a slide deck and host a webcast. The company focuses on developing innovative cancer therapeutics, including luxeptinib and APTO-253, aimed at treating various hematological malignancies.
Aptose Biosciences (NASDAQ: APTO) reported a net loss of $16.2 million for Q1 2021, up from $11.5 million in Q1 2020. Research and development expenses rose to $8.2 million, driven by increased costs for luxeptinib and APTO-253 trials. The company continues dose escalations in its Phase 1 a/b studies for luxeptinib in AML and B-cell malignancies. Dr. Jotin Marango has been appointed as Chief Financial Officer. Aptose maintains a solid cash position of $112.1 million, expected to support operations into 2023. Updates on clinical trials are anticipated at the upcoming EHA Virtual Congress in June.
FAQ
What is the current stock price of Aptose Biosciences (APTO)?
What is the market cap of Aptose Biosciences (APTO)?
What does Aptose Biosciences specialize in?
What is tuspetinib?
What are the recent achievements of Aptose Biosciences?
What is luxeptinib?
How does Aptose aim to improve the quality of life for cancer patients?
What financial activities has Aptose recently undertaken?
What are the main clinical trials conducted by Aptose?
What makes tuspetinib a potential candidate for accelerated approval?
How does Aptose integrate genetic insights into its drug development?